| Téléchargement | - Voir la version finale : A scalable serology solution for profiling humoral immune responses to SARS‐CoV‐2 infection and vaccination (PDF, 2.0 Mio)
|
|---|
| DOI | Trouver le DOI : https://doi.org/10.1002/cti2.1380 |
|---|
| Auteur | Rechercher : Colwill, KarenIdentifiant ORCID : https://orcid.org/0000-0002-8979-1659; Rechercher : Galipeau, Yannick; Rechercher : Stuible, Matthew1; Rechercher : Gervais, Christian1; Rechercher : Arnold, Corey; Rechercher : Rathod, Bhavisha; Rechercher : Abe, Kento T.; Rechercher : Wang, Jenny H.; Rechercher : Pasculescu, Adrian; Rechercher : Maltseva, Mariam; Rechercher : Rocheleau, Lynda; Rechercher : Pelchat, Martin; Rechercher : Fazel‐Zarandi, Mahya; Rechercher : Iskilova, Mariam; Rechercher : Barrios‐Rodiles, Miriam; Rechercher : Bennett, Linda; Rechercher : Yau, Kevin; Rechercher : Cholette, François; Rechercher : Mesa, Christine; Rechercher : Li, Angel X.; Rechercher : Paterson, Aimee; Rechercher : Hladunewich, Michelle A.; Rechercher : Goodwin, Pamela J.; Rechercher : Wrana, Jeffrey L.; Rechercher : Drews, Steven J.; Rechercher : Mubareka, Samira; Rechercher : McGeer, Allison J.; Rechercher : Kim, John; Rechercher : Langlois, Marc‐AndréIdentifiant ORCID : https://orcid.org/0000-0003-4652-3029; Rechercher : Gingras, Anne‐ClaudeIdentifiant ORCID : https://orcid.org/0000-0002-6090-4437; Rechercher : Durocher, Yves1Identifiant ORCID : https://orcid.org/0000-0002-2268-4111 |
|---|
| Affiliation | - Conseil national de recherches du Canada. Thérapeutique en santé humaine
|
|---|
| Bailleur de fonds | Rechercher : Genome Canada; Rechercher : Ontario Genomics; Rechercher : Canada Foundation for Innovation; Rechercher : Royal Bank of Canada; Rechercher : Canadian Institutes of Health Research; Rechercher : Public Health Agency of Canada; Rechercher : Ontario Ministry of Research, Innovation and Science; Rechercher : National Research Council Canada; Rechercher : Krembil Foundation |
|---|
| Format | Texte, Article |
|---|
| Sujet | antibody detection; antibody neutralisation; assaydevelopment and standardisation; high-throughput screening; SARS-CoV-2 |
|---|
| Résumé | Objectives: Antibody testing against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been instrumental in detecting previous exposures and analyzing vaccine-elicited immune responses. Here, we describe a scalable solution to detect and quantify SARS-CoV-2 antibodies, discriminate between natural infection- and vaccination-induced responses, and assess antibody-mediated inhibition of the spike-angiotensin converting enzyme 2 (ACE2) interaction.
Methods: We developed methods and reagents to detect SARS-CoV-2 antibodies by enzyme-linked immunosorbent assay (ELISA). The main assays focus on the parallel detection of immunoglobulin (Ig)Gs against the spike trimer, its receptor binding domain (RBD) and nucleocapsid (N). We automated a surrogate neutralisation (sn)ELISA that measures inhibition of ACE2-spike or -RBD interactions by antibodies. The assays were calibrated to a World Health Organization reference standard.
Results: Our single-point IgG-based ELISAs accurately distinguished non-infected and infected individuals. For seroprevalence assessment (in a non-vaccinated cohort), classifying a sample as positive if antibodies were detected for ≥ 2 of the 3 antigens provided the highest specificity. In vaccinated cohorts, increases in anti-spike and -RBD (but not -N) antibodies are observed. We present detailed protocols for serum/plasma or dried blood spots analysis performed manually and on automated platforms. The snELISA can be performed automatically at single points, increasing its scalability.
Conclusions: Measuring antibodies to three viral antigens and identify neutralising antibodies capable of disrupting spike-ACE2 interactions in high-throughput enables large-scale analyses of humoral immune responses to SARS-CoV-2 infection and vaccination. The reagents are available to enable scaling up of standardised serological assays, permitting inter-laboratory data comparison and aggregation. |
|---|
| Date de publication | 2022-03-23 |
|---|
| Maison d’édition | Wiley |
|---|
| Licence | |
|---|
| Dans | |
|---|
| Langue | anglais |
|---|
| Publications évaluées par des pairs | Oui |
|---|
| Exporter la notice | Exporter en format RIS |
|---|
| Signaler une correction | Signaler une correction (s'ouvre dans un nouvel onglet) |
|---|
| Identificateur de l’enregistrement | 6beb58c9-0acf-4a2a-820f-9099fe0c80e8 |
|---|
| Enregistrement créé | 2023-12-21 |
|---|
| Enregistrement modifié | 2023-12-21 |
|---|
